Because cytostasis is not a terminal state, breast cancer cells treated in the presence of IGF-1 could potentially escape antiestrogen- and/or antiprogestin-induced cytostasis via genetic or epigenetic changes that lead to the development of resistance. The gene discussed is IGF1; the disease is breast cancer.